Rituximab is a monoclonal antibody used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. It works by targeting CD20 on B-cells, leading to their destruction. Rituximab is effective for managing hematological malignancies. In summary, it is a vital therapy for specific blood cancers.
Rituximab binds to CD20 on B-cells, inducing apoptosis and mediating antibody-dependent cellular cytotoxicity.





